Alembic Pharma Receives USFDA Approval for Generic Chronic Constipation Treatment

pharmaceuticals

28 July 2026 at 11:30 pm

Alembic Pharma Receives USFDA Approval for Generic Chronic Constipation Treatment

HyperFast News

Summary

Alembic Pharmaceuticals has received final USFDA approval for its generic prucalopride tablets, indicated for chronic idiopathic constipation, which are therapeutically equivalent to Takeda's Motegrity.

Select what you want to create

Turn this story into an image post, carousel, video, audio reel, blog, and more — all from HyperFast News.

FAQ

Newsroom FAQs

About the public HyperFast News news feed powered by NewsEngine.